L. Daniel Browne
2013
In 2013, L. Daniel Browne earned a total compensation of $2.2M as President and Chief Executive Officer at Revance Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $60,540 |
|---|---|
| Option Awards | $1,759,189 |
| Salary | $384,387 |
| Total | $2,204,116 |
Browne received $1.8M in option awards, accounting for 80% of the total pay in 2013.
Browne also received $60.5K in non-equity incentive plan and $384.4K in salary.
Rankings
In 2013, L. Daniel Browne's compensation ranked 3,565th out of 12,286 executives tracked by ExecPay. In other words, Browne earned more than 71.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,565 out of 12,286 | 71st |
Division Manufacturing | 1,206 out of 4,612 | 74th |
Major group Chemicals And Allied Products | 329 out of 1,466 | 78th |
Industry group Drugs | 230 out of 1,160 | 80th |
Industry Pharmaceutical Preparations | 188 out of 890 | 79th |
Source: SEC filing on March 26, 2015.
Browne's colleagues
We found one more compensation record of an executive who worked with L. Daniel Browne at Revance Therapeutics in 2013.
2013
Jacob Waugh
Revance Therapeutics